SLC35B2 and melanoma: In contrast, upon treatment with Vemurafenib, SLC35B2 knockout clones of both cell types proliferated significantly slower, indicating that loss of SLC35B2 re-sensitized YAP5SA melanoma cells to Vemurafenib in vitro.